Media Pack
News

Current Edition

Volume 16 Issue 1
 
Regional News

GlaxoSmithKline vet departs for Vifor, the rumored target of a $7.1B CSL buyout

With a recent pruritus approval in the books and several more potential launches coming in the next year and a half, Switzerland’s Vifor Pharma is tapping longtime Gl...
13 December 2021 Regional News chief commercial officer | china
Continue Reading →
Regional News

GlaxoSmithKline and Vir’s sotrovimab stands up to omicron despite other COVID antibodies falling short

Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnolog...
8 December 2021 Regional News antibodies | Celltrion
Continue Reading →
Regional News

GSK’s ViiV looks to future of injectable HIV treatment as long-acting PrEP decision looms

The future of ViiV Healthcare's HIV business is injectable. By 2026, the majority-GlaxoSmithKline-owned joint venture expects long-acting regimens to generate around...
1 December 2021 Regional News Cabenuva | drug sales
Continue Reading →
Regional News

GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new home

GlaxoSmithKline isn’t just making changes with its U.S. operations. The company is now exploring a new location for its global headquarters amid a historic business r...
13 October 2021 Regional News GlaxoSmithKline | GSK
Continue Reading →
Regional News

GlaxoSmithKline relocates US operations in Philadelphia, North Carolina as COVID-19 cuts its office space needs

Many companies have shifted their way of working amid COVID-19. Adjusting to how work is done these days, GlaxoSmithKline is downsizing its office footprint in the U....
6 October 2021 Regional News biopharma | Excision BioTherapeutics
Continue Reading →
Regional News

GlaxoSmithKline’s long-acting HIV drug nabs FDA priority review as a preventative option

GlaxoSmithKline’s long-acting HIV drug cabotegravir is already challenging market leaders as part of an approved treatment regimen. Now, the medicine is a step closer...
29 September 2021 Regional News cabotegravir | FDA
Continue Reading →
Regional News

CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing push

As officials in Washington weigh contentious drug-pricing measures, there's even more evidence that pharma companies are worried about potential reform. In an open l...
16 September 2021 Regional News AbbVie | Biogen
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte